ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; [email protected]

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
01/11/201703:03:00Valeant Sheds Assets to Pay Down Debt -- WSJ
01/11/201703:03:00L'Oréal Expands Its Strategy -- WSJ
01/10/201717:11:00Current Report Filing (8-k)
01/10/201716:13:52Current Report Filing (8-k)
01/10/201714:31:00Valeant to Sell Skin-Care Brands to L'Oreal -- 2nd Update
01/10/201709:13:00L'Oréal Looks to Gain U.S. Share by Buying Valeant Brands...
01/10/201708:38:00L'Oréal Looks to Gain U.S. Share by Buying Valeant Brands
01/10/201706:00:00Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb...
01/10/201706:00:00Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study...
01/10/201706:00:00Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb...
01/10/201706:00:00Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study...
01/10/201704:30:00Valeant to Sell Skincare Brands to L'Oreal -- Update
01/10/201703:41:00L'Oreal to Buy 3 Skincare Brand from Valeant for $1.3 Billion
01/10/201703:17:00Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To...
01/10/201703:17:00Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To...
01/10/201703:02:00Valeant Agrees To Sell Dendreon -- WSJ
01/09/201723:49:00Valeant Agrees to Sell Dendreon to Sanpower for $820 Million
01/09/201722:40:00Valeant To Sell Dendreon To Sanpower Group For $819.9 Million...
01/09/201722:40:00Valeant To Sell Dendreon To Sanpower Group For $819.9 Million...
01/04/201717:03:41Current Report Filing (8-k)

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US